Nutriband (NTRB) said Wednesday it has received Hong Kong patent protection for its Aversa abuse-deterrence transdermal technology.
The company said it received a notice of publication of the registration and grant of a standard patent from the Hong Kong Intellectual Property Department for the technology.
The Aversa technology is now covered by patents issued in 46 countries and entities including the US, European Union, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
The technology places aversive agents into transdermal patches to counteract the abuse of opioids and stimulants.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.